The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
At moment an Unstable Company (3) but ok as a āGoing Concernā. Fair Value at Ā£300m Ā£1 a Share.
Launch Equity Value at now Ā£15m MCap.
New Company with Stability can return the Dividend sooner rather than re Stabilise the Balance Sheet over next 2 yrs.
This will significantly increase MCap Post Equity Raise as Ā£20m per Annum Profit is realistic on Ā£185m Revenue. Their Mission Statement is to Return 50% Profits to S/H Yr in Yr out. Thatās Ā£10m per Annum. Achieve this and the MCap will balance out.
Think of things in Reverse Order.
Hey Jay. Seems like a sensible target and a decent buy in. My buy in is slightly less , but I'm also cautious/ slightly pessimistic on my target sell. It's too hard to predict anything even though the SP should be 10+. Best of luck to us anyways . Personally I would like a 12p. But that being said and considering fair value I'd like it to hold that price too . I don't want it to spike up and then bleed and be stuck in limbo
What are your averages everyone? If ydm me asking
Faz knows exactly what it is. Heās bringing the subject up to try get in cheaper . No chance!
This is an excellent research note published two days ago which should answer all your questions Faz https://www.hardmanandco.com/wp-content/uploads/2020/07/NSF-June-2020-results-13-July-2020.pdf
21p target price.
Apologies but probably me being thick, when they say equity raise does that mean a dilution if shares, if so, from what I understand, that never really helps the share price?
Faz, this may help answer your question https://www.nasdaq.com/articles/subprime-lender-nsf-in-talks-for-equity-raise-sees-loan-book-steadying-by-q4-2020-07-15
Hey! Was looking for some info and opinions on what impact the equity raise will have and why are they doing one? I was on the assumption that they had a sufficient amount of capital headroom